All In Biotech

Drug Trial Radar · NCT00190411

Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type

Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome

Last checked: Nov 19, 2026Latest source record: Jan 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Oct 2003

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aventis Pharmaceuticals
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed that arteries are thin and overloaded in this patients. We test the protective effect of celiprolol on cardiovascular events in a 5 years, randomized, PROBE design

Conditions

  • EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT
  • CHROMOSOME 2q31.2 DELETION SYNDROME

Interventions

  • celiprololDrug

    celiprolol

  • ControlDrug

    Untreated controls excluding betablockers

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-upTime frame: during de study

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.